logo
Latest Oura Ring features focus on metabolic health improvement

Latest Oura Ring features focus on metabolic health improvement

Digital Trends06-05-2025

The Oura Ring 4 is rapidly becoming the center piece of your efforts to lead a healthier life, and the introduction of two new features designed to improve metabolic health back this up. The app now has an AI-powered food tracking feature called Meals, and integration with the Dexcom Stelo, the first glucose monitor available in the U.S. with Food and Drug Administration (FDA) approval and without a prescription.
The Meals feature has been part of Oura Labs, the brand's space for beta testing features, for a while and has now been elevated to become a permanent fixture in the app. It's a more advanced, less calorie-focused way of tracking your meals, which provides more information on how food may be affecting your health and wellbeing. It works by analyzing a photo of your meal, and examines the key nutritional elements within, before providing guidance on how to meet your goals.
Recommended Videos
Crucially, Oura emphasizes how Meals won't penalize your food choices, and won't judge based on what it 'sees' in the photo. Like Oura's decision to optionally minimize calorie burn as a goal, the focus on making better food choices through less aggressive methods to meet the personal goals specified in the app should help more people try the feature out.
The data from the Meals feature works with the integration of Dexcom's Stelo wearable to give Oura wearers greater insight into their metabolic health. Stelo is used worn on your upper arm and provides data on glucose levels, which is then integrated into the Oura Ring app. Dexcom's chief operating officer Jake Leach explains why it's a great pairing:
'Personalized guidance and insights are essential for helping people understand how their lifestyle choices affect their body, while also encouraging them to make informed health decisions that can improve their overall quality of life. By integrating with Oura, we're bringing the first glucose biosensor and smart ring integration to the market, providing a one-of-a-kind and personalized metabolic health experience that allows users to better understand the link between activity, sleep, stress, nutrition, and their glucose.'
Oura's vice president of science Shyamal Patel continued:
'Meal-induced glucose spikes can vary significantly due to factors like sleep, stress, exercise, and meal timing, which is why it's important to approach metabolic health holistically rather than focusing exclusively on diet. Instead of avoiding specific foods based on one spike, we encourage members to observe patterns, experiment with habits, and discover what helps them maintain better glucose balance over time. With this approach, members can maintain a healthy relationship with food while building long-term habits that support metabolic health.'
Both the Meals and Glucose features are available in the Oura Ring app in the U.S. now, with Meals expected to launch internationally later in 2025. Dexcom's Stelo wearable is only available in the U.S. and will be available through Oura's website for $99, and can be purchased with an Oura Ring as a bundle. However, this only provides Stelo biosensors for a single month of tracking, and it costs a further $99 every month afterwards. This is on top of the Oura Ring's $6 per month subscription to view most of the data in its app.
Please enable Javascript to view this content

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Mark Zuckerberg Personally Hiring to Create New 'Superintelligence' AI Team
Mark Zuckerberg Personally Hiring to Create New 'Superintelligence' AI Team

Bloomberg

time23 minutes ago

  • Bloomberg

Mark Zuckerberg Personally Hiring to Create New 'Superintelligence' AI Team

Mark Zuckerberg, frustrated with Meta Platforms Inc. 's shortfalls in AI, is assembling a team of experts to achieve artificial general intelligence, recruiting from a brain trust of AI researchers and engineers who've met with him in recent weeks at his homes in Lake Tahoe and Palo Alto. Zuckerberg has prioritized recruiting for the secretive new team, referred to internally as a superintelligence group, according to people familiar with his plans. He has an audacious goal in mind, these people said. In his view, Meta can and should outstrip other tech companies in achieving what's known as artificial general intelligence or AGI, the notion that machines can perform as well as humans at many tasks. Once Meta reaches that milestone, it could weave the capability into its suite of products — not just social media and communications platforms, but also a range of AI tools, including the Meta chatbot and its AI-powered Ray-Ban glasses.

CVD Mortality Higher in Women With Inflammatory Diseases
CVD Mortality Higher in Women With Inflammatory Diseases

Medscape

time30 minutes ago

  • Medscape

CVD Mortality Higher in Women With Inflammatory Diseases

Although cardiovascular disease (CVD)-related mortality decreased significantly from 1999 to 2020 in both men and women with immune-mediated inflammatory diseases (IMIDs), women consistently had higher rates of CVD-related mortality than men over the 22-year period. METHODOLOGY: Researchers analyzed CDC Multiple Cause of Death files from 1999 to 2020 to assess the sex differences in CVD-related mortality in patients with IMIDs. They identified CVD-related deaths with underlying IMIDs in the United States using diagnostic codes. IMIDs such as rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis were analyzed. The analysis included 281,355 IMID-related deaths and 127,149 CVD-related deaths over a period of 22 years. Annual crude and adjusted death rates were estimated. TAKEAWAY: Age-adjusted CVD-related mortality for women with IMIDs declined from 3.3 per 100,000 in 1999 to 1.4 per 100,000 in 2020, whereas the rate in men with IMIDs declined from 2.3 to 1.1 per 100,000 ( P < .01). < .01). However, women had higher mortality than men throughout the study duration (mortality rate ratio, 1.5; P < .01). < .01). Cerebrovascular disease and ischemic heart disease were major causes of death, with women more affected than men; women experienced mortality from arrhythmia and cardiac arrest at more than twice the rate of men. Among patients with IMIDs, women with rheumatoid arthritis had disproportionately higher crude CVD-related mortality than men with rheumatoid arthritis. IN PRACTICE: 'Addressing these risks requires increasing awareness of atypical cardiovascular symptoms in females with IMIDs, enhancing early detection through advanced imaging, and ensuring equitable access to therapies like biologics,' the study authors wrote. SOURCE: This study was led by Issam Motairek, MD, Cleveland Clinic, Cleveland. It was published online on May 5, 2025, in Circulation: Cardiovascular Quality and Outcomes . LIMITATIONS: The potential inaccuracies in the codes for identifying the cause of death may have misclassified IMIDs or CVD-related causes. The aggregate data structure prevented the analyses of individual-level factors such as severity of disease or treatments. Less common IMIDs were excluded, which may have underestimated their contribution to CVD. DISCLOSURES: This study received no specific funding. The authors reported having no conflicts of interest.

Watch These AMD Price Levels as Stock Jumps to Highest Level Since January
Watch These AMD Price Levels as Stock Jumps to Highest Level Since January

Yahoo

time31 minutes ago

  • Yahoo

Watch These AMD Price Levels as Stock Jumps to Highest Level Since January

Advanced Micro Devices shares closed at their highest level since January on Monday, lifted by optimism that trade discussions between the U.S. and China could lead to reduced export curbs. After breaking out from a descending broadening formation last month, AMD shares have traded mostly sideways just below the closely watched 200-day moving average. Investors should monitor major overhead areas on AMD's chart around $123, $145 and $175, while also watching a key support level near $ Micro Devices (AMD) shares will likely remain in focus after hitting their highest level since January on Monday, lifted by optimism that trade discussions between the U.S. and China could lead to reduced export curbs. Chipmakers rallied after White House National Economic Council Director Kevin Hassett said on CNBC early Monday that officials from Washington and Beijing intended to discuss the release of rare earth minerals to the U.S. and the expansion of Chinese access to American-made semiconductors during talks between the two countries taking place in London this week. In April, AMD cautioned its results would be affected by charges of roughly $800 million related to tightening restrictions on sales of its chips to China, while rival AI behemoth (NVDIA) warned it would take a potential $5.5 billion charge related to limits on exports of its H20 chip. AMD shares gained nearly 5% on Monday to close at around $122. The stock has risen nearly 60% from its early April-low, putting it back to where it started 2025, as investors assess whether the company can make further inroads into the booming AI chip market. Investors will learn more about AMD's plans for artificial intelligence at the company's "Advancing AI" event on Thursday, which features a keynote address from CEO Lisa Su. Below, we take a closer look at AMD's chart and use technical analysis to identify major price levels that investors will likely be monitoring. After breaking out from a descending broadening formation last month, AMD shares have traded mostly sideways just below the closely watched 200-day moving average (MA). More recently, the stock's price has nudged toward the May high, a move that has coincided with the relative strength index indicating strengthening price momentum. It's also worth pointing out that the shares registered their highest trading volume in nearly a month on Monday, indicating growing interest in the chipmaker's stock. Let's identify three major overhead areas on AMD's chart to monitor if the shares continue to trend higher and also locate a key support level worth watching during possible retracements. The first overhead area to monitor sits around $123. This area may provide resistance near the May swing high, which also closely aligns with last year's prominent early-August sell-off swing low. A decisive close above the 200-day MA could spark a rally toward $145. The shares may run into selling pressure in this location near a trendline that connects a range of corresponding trading activity on the chart between April and December last year. Further buying could see the stock's price test higher overhead resistance around $175. Investors who have accumulated shares at lower levels may decide to lock in profits in this region near notable peaks that developed on the chart in May and October 2024. During retracements in the stock, investors should keep a close eye on the $108 level. This area on the chart would likely attract buying interest near last month's pullback low and the stock's early-February trough. The comments, opinions, and analyses expressed on Investopedia are for informational purposes only. Read our warranty and liability disclaimer for more info. As of the date this article was written, the author does not own any of the above securities. Read the original article on Investopedia

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store